Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (06990) has entered into a structured deposit agreement with Bank of China, committing to invest RMB 440 million in structured deposits, which are expected to yield higher returns than traditional bank deposits [1] Summary by Relevant Sections - **Investment Details** - The company has agreed to subscribe to structured deposits amounting to RMB 440 million with Bank of China [1] - The structured deposits are characterized as capital-protected financial products with floating returns [1] - **Expected Benefits** - The anticipated return rate from these structured deposits is expected to exceed that of general commercial bank deposits [1] - This investment is aimed at improving the efficiency of the company's idle funds [1] - **Management's Perspective** - The board believes that the terms of the structured deposit agreement are fair and reasonable [1] - The investment aligns with the overall interests of the company's shareholders [1]

格隆汇9月29日丨科伦博泰生物-B(06990.HK)公告，2025年9月29日，公司订立中国银行结构性存款协 议，据此，公司同意认购本金额为人民币4.4亿元的中国银行结构性存款。 ...

Core Viewpoint - Kolunbotai Biotech-B (06990) has entered into a structured deposit agreement with Bank of China, committing to subscribe to a structured deposit amounting to RMB 440 million, which is expected to yield higher returns than typical commercial bank deposits [1] Group 1 - The structured deposit is characterized as a capital-protected financial product with floating returns, indicating a strategic move to enhance the efficiency of the company's idle funds [1] - The anticipated return rate and the short to medium-term nature of the financial product are highlighted as key factors in the decision to invest in the structured deposit [1] - The board of directors believes that the terms of the structured deposit are fair and reasonable, aligning with the overall interests of the company's shareholders [1]